Multiple clinical trials (including KEYNOTE-024, IMpower110, etc.)confirmed that NSCLC patients with high PD-L1 expression tended to achieve better survival benefits when treated with PD-1/PD-L1 inhibitors [3, 90]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.